Gene Therapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
Researchers from Baylor College of Medicine, College of Medicine report details of new studies and findings in the area of gene therapy
May 29th, 2008
According to recent research from the United States, "Hypoxia occurs in many tumors and reduces the effectiveness of radio- (a)nd chemotherapy. Hypoxia also impedes immune responses to tumors, reducing T lymphocyte production of cytokines such as interleukin- (2) (IL- 2) and interferon gamma, as well as the survival and proliferation of these cells." "We constructed a lentiviral vector encoding a bidirectional hypoxia- (i)nducible responsive element ( HRE) derived from human vascular endothelial growth factor, which drives the hIL- (2)gene and a marker gene. We used a model of human B cell lymphoma to show that tumor-specific T cells modified with this vector upregulate...
Source: Gene Therapy Weekly (2008-05-29)
|
